TSX · L.TO
Loblaw Companies Limited
CA$68.50+CA$0.52 (+0.76%)
Loblaw Companies Limited’s quoted price sits in the upper half of its reported 52-week range, 3.6% below the high.
Loading market information…
OTC · CEOS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 02:31 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
CeCors, Inc.’s quoted price sits in the upper half of its reported 52-week range, 38.89% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow CeCors, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
CeCors, Inc. engages in the acquisition and development of healthcare companies focusing on military veterans. It operates through the PsyKey and VETCOMM segments. The PsyKey segment refers to consumer goods. It is related to the sales of coffee products. The VETCOMM segment includes recurring services such as education and resources. The company was founded on April 16, 2002 and is headquartered in Toronto, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$68.50+CA$0.52 (+0.76%)
Loblaw Companies Limited’s quoted price sits in the upper half of its reported 52-week range, 3.6% below the high.
CA$205.89+CA$3.90 (+1.93%)
Dollarama Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.94% below the high.
CA$106.35+CA$1.45 (+1.38%)
George Weston Limited’s quoted price sits in the upper half of its reported 52-week range, 4.61% below the high.
CA$95.35+CA$0.56 (+0.59%)
Metro Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.87% below the high.
$0.00$0.00 (0.0%)
Health Discovery Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Instadose Pharma Corp.’s quoted price sits in the lower half of its reported 52-week range, 90.91% below the high.
$0.00$0.00 (0.0%)
Health Advance Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
Nanobac Pharmaceuticals, Incorporated’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
